一种识别神经细胞黏附分子的放射性标记单克隆抗体NY3D11在肿瘤异种移植模型和小细胞肺癌患者中的生物分布。
Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer.
作者信息
Ornadel D, Ledermann J A, Eagle K, Pedley R B, Boxer G, Ward S E, Olabiran Y, Bomanji J
机构信息
Department of Oncology, UCL Medical School, London, UK.
出版信息
Br J Cancer. 1998;77(1):103-9. doi: 10.1038/bjc.1998.16.
The neural cell adhesion molecule (NCAM) is highly expressed on the surface of small-cell-lung cancer (SCLC) cells. We have produced a monoclonal antibody, NY3D11, that binds to NCAM to investigate whether this antigen could be used to develop antibody-directed therapy for SCLC. 125I-labelled IgG and F(ab')2 fragments of NY3D11 localized selectively in human SCLC xenografts grown in nude mice. The human biodistribution of 131I-labelled NY3D11 after intravenous administration was investigated by gamma-camera imaging in six patients with SCLC. Three patients received IgG and three received F(ab')2. No evidence of localization to primary tumours or metastases was seen and antibody accumulated rapidly in the liver and bone marrow. The probable explanation for this distribution is that NY3D11 reacted with soluble NCAM or natural killer cells that possess the CD56 (NCAM) antigen.
神经细胞黏附分子（NCAM）在小细胞肺癌（SCLC）细胞表面高度表达。我们制备了一种与NCAM结合的单克隆抗体NY3D11，以研究该抗原是否可用于开发针对SCLC的抗体导向疗法。125I标记的NY3D11 IgG和F(ab')2片段选择性地定位于裸鼠体内生长的人SCLC异种移植瘤中。通过γ相机成像研究了6例SCLC患者静脉注射131I标记的NY3D11后的人体生物分布。3例患者接受了IgG，3例接受了F(ab')2。未观察到抗体定位于原发性肿瘤或转移灶的证据，且抗体在肝脏和骨髓中迅速蓄积。这种分布的可能解释是NY3D11与可溶性NCAM或具有CD56（NCAM）抗原的自然杀伤细胞发生了反应。
Zotero 插件